JACC:呼吸系统疾病与心血管发病呈独立相关性!

2019-05-07 不详 MedSci原创

呼吸疾病与心血管病的相关性尚不清楚,本研究的目的旨在评估慢阻肺(COPD)、哮喘、间质性肺病(ILD)与心血管疾病的相关性。本研究纳入了2000-2013年来自7个医学中心的呼吸系统疾病患者,包括31646名COPD、60424名哮喘和1662名ILD患者,经过平均2968182人年时间的随访,发现COPD与缺血性心脏病、心衰、房颤和外周血管疾病呈独立相关性,且所有这些均与全因死亡率的增高相关,哮

呼吸疾病与血管病的相关性尚不清楚,本研究的目的旨在评估慢阻肺(COPD)、哮喘、间质性肺病(ILD)与血管疾病的相关性。

本研究纳入了2000-2013年来自7个医学中心的呼吸系统疾病患者,包括31646名COPD、60424名哮喘和1662名ILD患者,经过平均2968182人年时间的随访,发现COPD与缺血性心脏病、心衰房颤和外周血管疾病呈独立相关性,且所有这些均与全因死亡率的增高相关,哮喘与缺血性心脏病相关,且可增加全因死亡风险。另外,ILD与缺血性心脏病和心衰呈独立相关,同时可增加死亡风险。肺疾病患者接受冠脉血管再生的概率更小。

研究结果显示,呼吸系统疾病与心血管疾病发生呈独立相关性,尤其是缺血性心脏病和心衰,且可增加死亡风险。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854381, encodeId=dee91854381bb, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 28 13:33:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837681, encodeId=0242183e681ab, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 12 09:33:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326202, encodeId=654a132620257, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 09 11:33:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419017, encodeId=fb12141901ede, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Thu May 09 11:33:00 CST 2019, time=2019-05-09, status=1, ipAttribution=)]
    2019-10-28 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854381, encodeId=dee91854381bb, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 28 13:33:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837681, encodeId=0242183e681ab, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 12 09:33:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326202, encodeId=654a132620257, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 09 11:33:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419017, encodeId=fb12141901ede, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Thu May 09 11:33:00 CST 2019, time=2019-05-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854381, encodeId=dee91854381bb, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 28 13:33:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837681, encodeId=0242183e681ab, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 12 09:33:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326202, encodeId=654a132620257, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 09 11:33:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419017, encodeId=fb12141901ede, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Thu May 09 11:33:00 CST 2019, time=2019-05-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854381, encodeId=dee91854381bb, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 28 13:33:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837681, encodeId=0242183e681ab, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 12 09:33:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326202, encodeId=654a132620257, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 09 11:33:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419017, encodeId=fb12141901ede, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Thu May 09 11:33:00 CST 2019, time=2019-05-09, status=1, ipAttribution=)]

相关资讯

JACC:高密度脂蛋白相关评分可预测冠心病的发生和死亡

循环血中的脂蛋白浓度与冠心病的发病风险呈强相关。本研究的目的旨在高密度脂蛋白(HDL)体学评分(pCAD)对冠心病诊断和预后的影响。本研究对 CASABLANCA临床研究中的943名无心梗冠脉造影患者进行了HDL相关脂蛋白apoA1, apoC-1, apoC-2, apoC-3和apoC-4进行了检测,经过平均4年时间的随访,有587名患者出现了冠脉梗阻,pCAD评分与梗阻性冠心病的发生呈相关性

NATURE:外化的组蛋白H4可协调心血管疾病

炎症的持续存在是造成全球医疗负担的重要病理生理因素。非程序性细胞死亡促进慢性炎症。然而,至今为止,关于炎症是如何激发的,其细胞和分子介质及其治疗价值的定义还不明确。

J Hypertens:高血压和多种心血管危险因素会增加视网膜静脉阻塞的风险

由此可见,心血管危险因素比RVO存在的其他危险因素更重要。增加任何一个额外的危险因素,RVO的风险增加约40%,增加任何一个额外的心血管危险因素风险增加70%。

JACC:经导管二尖瓣修复术能改善心衰伴二尖瓣反流患者的健康状况

在COAPT临床试验中,经导管二尖瓣修复术(TMVr)可以降低心衰伴3-4级继发性二尖瓣反流(MR)患者的心衰住院率并增加生存率。本研究的目的旨在比较评估接受TMVr治疗和标准治疗的心衰伴3-4级继发性MR患者的健康状况。COAPT临床试验将心衰伴3-4级继发性MR患者随机分成TMVr治疗组(n=302)和标准治疗(n=312),患者的健康状态在基线、治疗后1个月、6个月、12个月和24个月进行评

盘点:JACC四月第四期研究一览

1. 冠脉搭桥手术的当代预后优于以往